Akiram Therapeutics, a Swedish biotech company specializing in targeted radiotherapy, will contribute to several academic presentations at the EANM Congress 2025 in Barcelona, October 4–8. Two have been selected as top rated oral presentations, highlighting continued development of the CD44v6-targeting antibody used in the company’s clinical-stage radiopharmaceutical—currently being investigated in a Phase I clinical trial.
This marks the second consecutive year that research involving Akiram’s CD44v6-targeting platform has been selected for oral presentation at EANM. The 2025 contributions stem from ongoing work in Professor Marika Nestor’s academic group at Uppsala University, exploring novel strategies such as expanding to additional radioisotopes, combination treatment, and dosimetry approaches for CD44v6-targeted radionuclide therapy. The work complements the ongoing clinical evaluation of the radiopharmaceutical candidate in advanced solid tumors.
“We’re honored to once again be part of the EANM Congress,” says Marika Nestor, CEO of Akiram Therapeutics. “It’s encouraging to see how the scientific foundation of our CD44v6 platform continues to grow—while our clinical candidate moves through its first human trial. These efforts reflect our long-standing commitment to collaboration, innovation, and patient impact.”
Presentations at EANM 2025
- Oral Presentation (Top Rated)
Title: Tb, or Not Tb – Exploring Terbium-161 for CD44v6-Targeted Radionuclide Therapy
Presentation No.: OP-414
Date & Time: October 6, 3:30 PM, Room 114
Speaker: Amanda Gustafsson
- Oral Presentation (Top Rated)
Title: Combining CD44v6-Targeted Radionuclide Therapy with Chemotherapy for Treatment of Pancreatic Ductal Adenocarcinoma
Presentation No.: OP-519
Date & Time: October 7, 8:40 AM, Room 114
Speaker: Amanda Gustafsson
- e-Poster
Title: Optimizing CD44v6-Targeted Radioimmunotherapy: A Retrospective Red Marrow Dosimetry Comparison of 186Re, 177Lu, and 161Tb
Poster No.: EP-1160
Date: October 4–8, during congress hours
Author: Jens Hemmingsson
CD44v6 is a cell surface marker found in several aggressive cancer types, making it a relevant target for precision radiotherapy. The antibody targeting CD44v6 is also used in Akiram’s radiopharmaceutical candidate 177Lu-AKIR001, which is currently being evaluated in a Phase I trial sponsored by Karolinska University Hospital. The study assesses safety and pharmacokinetics in patients with advanced solid tumors. The trial is registered at ClinicalTrials.gov: NCT06639191.
